EUVIMEDEUVIMED entdecken
Open Access

Clinicomolecular Profile and Efficacy of Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Therapy for HER2 -Amplified Advanced Biliary Tract Cancer

Kanae Inoue iD, Yoshiaki Nakamura iD, Bennett Caughey iD, Binbin Zheng-Lin, Makoto Ueno iD, Masayuki Furukawa iD, Yasuyuki Kawamoto iD, Shinji Itoh iD, Kumiko Umemoto iD, Kentaro Sudo, Taroh Satoh iD, Nobumasa Mizuno iD und 8 weitere

JCO Precision Oncology · 2025-04 · (9)

DOI: 10.1200/po-24-00718 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2025-04. Verfasst von Kanae Inoue und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Biliary Tract Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE This study aimed to investigate the clinicomolecular profiles and the efficacy of human epidermal growth factor receptor 2 (HER2)-targeted therapy in HER2 -amplified biliary tract cancer (BTC). METHODS This study was an international collaboration that used combined data from the prospective SCRUM-Japan GOZILA and MONSTAR-SCREEN in Japan and retrospective reviews in the United States; patients with advanced BTC who had received systemic therapy were included. The clinicomolecular profiles were evaluated in an exploratory cohort, whereas the efficacy of HER2-targeted therapy was assessed in a biomarker-selected cohort. RESULTS Of the 439 patients in the exploratory cohort, 43 (10%) had HER2 amplification. The frequencies of coalterations were higher in patients with HER2 amplification versus patients without HER2 amplification including HER2 mutations (26% v 5%, P < .001), TP53 mutations (84% v 61%, P = .003), and BRAF amplification (9% v 2%, P = .030). There were no KRAS mutations identified in patients with HER2- amplified BTC. No significant difference in overall survival (OS) was observed between patients with and without HER2 amplification (median, 17.7 v 16.9 months; hazard ratio [HR], 0.95 [95% CI, 0.65 to 1.40]). Of the 60 patients with HER2 -amplified BTC in the biomarker-selected cohort (43 from Japan and 17 from the United States), the OS was significantly longer in 29 patients who received HER2-targeted therapy than in those who did not receive HER2-targeted therapy (median, 24.3 v 12.1 months; HR, 0.39 [95% CI, 0.23 to 0.82]). Multivariate analysis identified HER2-targeted therapy as an independent prognostic factor for OS (HR, 0.29 [95% CI, 0.14 to 0.58]; P < .001). CONCLUSION HER2 amplification was found in 10% of advanced BTC and was not identified as an independent prognostic factor for OS. Patients with HER2 -amplified BTC derive significant benefit from HER2-targeted therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesBiliary Tract NeoplasmsHumansFemaleMaleMiddle AgedAgedMolecular Targeted TherapyRetrospective StudiesJapanAged, 80 and overAdultProspective StudiesGene Amplification

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, human

Autor:innen und Institutionen

  • Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Translational Research Support Office, Division of Drug and Diagnostic Development Promotion, Department for the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East, Kashiwa, Japan.
  • Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA.
  • Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ.
  • Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.

ORCID-Profile: Kanae Inoue, Yoshiaki Nakamura, Bennett Caughey, Makoto Ueno, Masayuki Furukawa, Yasuyuki Kawamoto, Shinji Itoh, Kumiko Umemoto, Taroh Satoh, Nobumasa Mizuno, Takeshi Kajiwara, Takao Fujisawa, Hideaki Bando, Takayuki Yoshino, John H Strickler, Chigusa Morizane, Tanios Bekaii-Saab, Masafumi Ikeda

Zitieren

APA

Inoue, K., Nakamura, Y., Caughey, B., Zheng-Lin, B., Ueno, M., Furukawa, M., Kawamoto, Y., Itoh, S., Umemoto, K., Sudo, K., Satoh, T., Mizuno, N., Kajiwara, T., Fujisawa, T., Bando, H., Yoshino, T., Strickler, J. H., Morizane, C., Bekaii-Saab, T., & Ikeda, M. (2025). Clinicomolecular Profile and Efficacy of Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Therapy for HER2 -Amplified Advanced Biliary Tract Cancer. JCO Precision Oncology. https://doi.org/10.1200/po-24-00718

Vancouver

Inoue K, Nakamura Y, Caughey B, Zheng-Lin B, Ueno M, Furukawa M, et al. Clinicomolecular Profile and Efficacy of Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Therapy for HER2 -Amplified Advanced Biliary Tract Cancer. JCO Precision Oncology. 2025. doi:10.1200/po-24-00718

BibTeX
@article{Inoue2025,
  author = {Inoue, Kanae and Nakamura, Yoshiaki and Caughey, Bennett and Zheng-Lin, Binbin and Ueno, Makoto and Furukawa, Masayuki and Kawamoto, Yasuyuki and Itoh, Shinji and Umemoto, Kumiko and Sudo, Kentaro and Satoh, Taroh and Mizuno, Nobumasa and Kajiwara, Takeshi and Fujisawa, Takao and Bando, Hideaki and Yoshino, Takayuki and Strickler, John H and Morizane, Chigusa and Bekaii-Saab, Tanios and Ikeda, Masafumi},
  title = {Clinicomolecular Profile and Efficacy of Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Therapy for HER2 -Amplified Advanced Biliary Tract Cancer},
  journal = {JCO Precision Oncology},
  year = {2025},
  number = {9},
  doi = {10.1200/po-24-00718}
}
Kostenlos starten →